SPECIAL

The CTLA-4 and PD-1/PD-L1 pathways: leading the way in cancer immunotherapy

Tom Feys

Immuno-oncology in lung cancer

P. Germonpré, J. Lamont

How immune checkpoint inhibition reshaped advanced melanoma

J-F. Baurain

Broadening the possibilities for checkpoint inhibitors

Tom Feys

Immune checkpoint inhibitors in clinical practice: management of immune-related toxicities

B. Neyns

The financial toxicity of cancer immunotherapy

P. Specenier